Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis

Annals of the Rheumatic Diseases

Volumn 64, Issue 8, 2005, Pages 1199-1204

  Nieten, M M J ^b   Van Der Horst, A R ^c   Van Schaardenburg, D ^b   Van Der Horst Bruinsma, I E ^d   Van De Stadt, R J ^b   Aarden, L ^e   Dijkmans, B A C ^d   Hamann, Dörte ^a,c  

^a Sanquin Diagnostiek   (Netherlands)

^b JAN VAN BREEMEN INSTITUTE   (Netherlands)

^c CENTRAL LABORATORY   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e SANQUIN RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CITRULLINATED HUMAN FIBRINOGEN ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ARTHRITIS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; CITRULLINE; EPIDEMIOLOGIC METHODS; FEMALE; FIBRINOGEN; HUMANS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PROGNOSIS; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX;

EID: 23444461155     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.029389     Document Type: Article

References (34)

1. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
2. Saraux A, Berthelot JM, Chales G, Le Henaff C, Thorel JB, Hoang S, et al. Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later. Arthritis Rheum 2001;44:2485-91.
3. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101:273-81.
4. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
5. Zendman AJ, Vossenaar ER, van Venrooij WJ. Autoantibodies to citrullinated (poly)peptides: a key diagnostic and prognostic marker for rheumatoid arthritis. Autoimmunity 2004;37:295-9.
6. van Venrooij WJ, Hazes JM, Visser H. Anticitrullinated protein/peptide antibody ana its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med 2002;60:383-8.
7. Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000;2:236-43.
8. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Hof M, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
9. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002;46:357-65.
10. Jansen AL, van DH-B, I, van Schaardenburg D, van de Stadt RJ, de Koning MH, Dijkmans BA. Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 2002;29:2074-6.
11. Veneovsky J, Machacek S, Sedova L, Kafkova J, Galterova J, Pesakova V, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003;62:427-30.
12. Smeets TJ, Vossenaar ER, Kraan MC, van Mansum WAM, Raats JM, van Venrooij WJ, et al. Expression of citrullin-containing antigens in RA synovium [abstract]. Arthritis Res, 2001;3(2 (P4)).
13. Baeten D, Peene I, Union A, Meheus L, Sebbag M, Serre G, et al. Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis Rheum 2001;44:2255-62.
14. Reparon-Schuijt CC, van Esch WJ, van Kooten C, Schellekens GA, de Jong BA, van Venrooij WJ, et al. Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum 2001;44:41-7.
15. Masson-Bessiere C, Sebbag M, Durieux JJ, Nogueira L, Vincent C, Girbal-Neuhauser E, et al. In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol 2000;119:544-52.
16. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 2001;166:4177-84.
17. Nogueira L, Sebbag M, Chapuy-Regaud S, Clavel C, Fournie B, Cantagrel A, et al. Autoantibodies to deiminated fibrinogen are the most efficient serological criterion for the diagnosis of rheumatoid arthritis [abstract]. Arthritis Res, 2002;4(suppl 1)..
18. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
19. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
20. van der Heijde DM, van Leeuwen MA, van Riel PLCM, Koster AM, van't Hof MA, van Rijswijk MH, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992;35:26-32.
21. Nogueira L, Sebbag M, Vincent C, Arnaud M, Fournie B, Cantagrel A, et al. Performance of two ELISAs for antifilaggrin autoantibodies, using either affinity purified or deiminated recombinant human filaggrin, in the diagnosis of rheumatoid arthritis. Ann Rheum Dis 2001;60:882-7.
22. Nissinen R, Paimela L, Julkunen H, Tienari PJ, Leirisalo-Repo M, Palosuo T, et al. Peptidylarginine deiminase, the arginine to citrulline converting enzyme, is frequently recognized by sera of patients with rheumatoid arthritis, systemic lupus erythematosus and primary Sjogren syndrome. Scand J Rheumatol 2003;32:337-42.
23. Bruynesteyn K, van der HD, Boers M, Soudan A, Peloso P, Paulus H, et al. Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum 2002;46:913-20.
24. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004;50:709-15.
25. Nogueira L, Chapuy-Regaud S, Constantin A, Clavel C, Sebbag M, Cantagrel A, et al. Autoantibodies to deiminated fibrinogen are the most efficient serological criterion for early rheumatoid arthritis diagnosis [abstract]. Arthritis Res Ther, 2003;5(suppl 1, (18)):S6.
26. Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003;62:120-6.
27. Jansen LMA, van Schaardenburg D, van der Horst Bruinsma IE, van de Stadt RJ, de Koning MHMT, Dijkmans BAC. The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis. J Rheumatol 2003;30:1691-5.
28. Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004;63:1090-5.
29. Doyle HA, Mamula MJ. Post-translational protein modifications in antigen recognition and autoimmunity. Trends Immunol 2001;22:443-9.
30. Monneaux F, Muller S. Epitope spreading in systemic lupus erythematosus: identification of triggering peptide sequences. Arthritis Rheum 2002;46:1430-8.
31. Aho K, Heliovaara M, Maatela J, Tuomi T, Palosuo T. Rheumatoid factors antedating clinical rheumatoid arthritis. J Rheumatol 1991;18:1282-4.
32. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
33. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
34. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E. The conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003;171:538-41.